IPC분류정보
국가/구분 |
United States(US) Patent
등록
|
국제특허분류(IPC7판) |
|
출원번호 |
US-0654761
(2003-09-04)
|
등록번호 |
US-7497855
(2009-03-03)
|
발명자
/ 주소 |
- Ausiello,Dennis
- Santini, Jr.,John T.
- Herman,Stephen J.
- Prescott,James H.
- Uhland,Scott A.
- Maloney,John M.
- Polito,Benjamin F.
|
출원인 / 주소 |
|
대리인 / 주소 |
Sutherland Asbill & Brennan LLP
|
인용정보 |
피인용 횟수 :
30 인용 특허 :
37 |
초록
▼
Method and devices are provided for extended and controlled delivery of parathyroid hormone to a patient. The method includes implanting a medical device into the patient, the medical device comprising a substrate, a plurality of reservoirs in the substrate, a release system contained in each of the
Method and devices are provided for extended and controlled delivery of parathyroid hormone to a patient. The method includes implanting a medical device into the patient, the medical device comprising a substrate, a plurality of reservoirs in the substrate, a release system contained in each of the reservoirs, wherein the release system comprises parathyroid hormone; and controllably releasing a pharmaceutically effective amount of the parathyroid hormone from the reservoirs. The parathyroid hormone can be released intermittently, such as once daily over an extended period (e.g., two months, ten months, or more.). The device can further include reservoirs containing a bone resorption inhibitor or other drug for release. The devices are useful in delivering PTH for the treatment and prevention of bone loss, such as associated with osteoporosis.
대표청구항
▼
We claim: 1. A method for controlled delivery of parathyroid hormone to a patient in need thereof comprising: implanting a medical device into the patient, the medical device comprising: a substrate having a plurality of reservoirs, a release system contained in each of the reservoirs, wherein the
We claim: 1. A method for controlled delivery of parathyroid hormone to a patient in need thereof comprising: implanting a medical device into the patient, the medical device comprising: a substrate having a plurality of reservoirs, a release system contained in each of the reservoirs, wherein the release system comprises parathyroid hormone, and a plurality of discrete reservoir caps, each being in register with an opening of one of the reservoirs, separating the release system from an environment outside of the reservoirs, and preventing the parathyroid hormone from being released from the medical device; passing an electric current through one or more of the discrete reservoir caps, via an electrical input lead and an electrical output lead which are electrically connected to said reservoir cap, to disintegrate the one or more discrete reservoir caps by electrothermal ablation, thereby to expose to the environment the release system contained in the one or more reservoirs corresponding to the disintegratd one or more reservoir caps; and releasing a pharmaceutically effective amount of the parathyroid hormone from the one or more reservoirs corresponding to the disintegrated one or more reservoir caps. 2. The method of claim 1, wherein the parathyroid hormone is released intermittently from the medical device. 3. The method of claim 1, wherein the parathyroid hormone is released daily in intermittent doses of between about 10 and 300 μg. 4. The method of claim 3, wherein the daily intermittent doses are released over a period of ten months or more. 5. The method of claim 1, wherein the parathyroid hormone is released in a pulsatile manner, each pulse having a duration of less than four hours. 6. The method of claim 1, wherein the pharmaceutically effective amount of the parathyroid hormone, released over a first period of time, is effective to form bone tissue. 7. The method of claim 6, further comprising administering a pharmaceutically effective amount of a bone resorption inhibitor, released over a second period of time, to maintain bone tissue at a level present after the first period of time. 8. The method of claim 7, wherein the bone resorption inhibitor is selected from the group consisting of bisphosphonates, selective estrogen receptor modulators, calcitonins, vitamin D analogs, and calcium salts. 9. The method of claim 6, wherein the bone resorption inhibitor is administered orally. 10. The method of claim 6, wherein the bone resorption inhibitor is released from one or more reservoirs in the medical device. 11. An implantable device for controlled delivery of parathyroid hormone to a patient in need thereof comprising: a substrate having a plurality of reservoirs; a release system contained in each of the reservoirs, wherein the release system comprises parathyroid hormone; a plurality of discrete reservoir caps, each reservoir cap comprising a metal film in register with an opening of one of the reservoirs, separating the release system from an environment outside of the reservoirs, and preventing the parathyroid hormone from being released from the implantable device; and means for disintegrating one or more of the discrete reservoir caps by electrothermal ablation to release the parathyroid hormone from one or more of the reservoirs, wherein the means for disintegrating comprises (i) an electrical input lead and an electrical output lead which are electrically connected to at least one of said reservoir caps, (ii) a power source, and (iii) a control means for controlling application of an electric current from the power source through said at least one of the reservoir caps, via the input and output leads. 12. The device of claim 11, which is able to release a pharmaceutically effective amount of parathyroid hormone once daily over a period of at least six months. 13. The device of claim 11, further comprising at least one reservoir which contains a second release system comprising a drug other than parathyroid hormone. 14. The device of claim 13, wherein the drug is an anti-resorptive agent. 15. The device of claim 11, wherein each of the reservoirs contains between about 10 and 300 μg of parathyroid hormone for release. 16. The device of claim 11, wherein the plurality of reservoirs comprises 300 or more reservoirs, each containing a release system comprising parathyroid hormone. 17. The device of claim 11, wherein the release system comprises parathyroid hormone in combination with a pharmaceutically acceptable excipient. 18. The device of claim 11, wherein the release system comprises parathyroid hormone suspended in a non-aqueous vehicle. 19. The device of claim 17, wherein the parathyroid hormone is dried or lyophilized with an excipient that promotes re-dissolution upon release. 20. The device of claim 17, wherein the excipient comprises polyethylene glycol having a molecular weight between about 100 and 10,000 Daltons. effective to electrothermally ablate said at least one reservoir cap. 21. The device of claim 11, further comprising a sensor. 22. The device of claim 11, capable of vaginal administration of the parathyroid hormone. 23. The device of claim 11, wherein the body comprises silicon and the reservoir cap comprises at least one metal film. 24. The device of claim 23, wherein the reservoir cap comprises a multi-layer structure comprising platinum and titanium. 25. An implantable device for controlled delivery of parathyroid hormone to a patient in need thereof comprising: a body having a plurality of reservoirs; a release system contained in each of the reservoirs, wherein the release system comprises parathyroid hormone; an electrically conductive reservoir cap covering a discrete, predefined opening in each reservoir; a conducting input lead and a conducting output lead each of which are physically and electrically connected to each reservoir cap; and a power source and a controller for selectively delivering an electric current through the reservoir cap via the conducting leads effective to rupture the reservoir cap and release a pharmaceutically effective amount of the parathyroid hormone from the reservoir. 26. The device of claim 25, wherein the release system comprises multiple layers of release system having different compositions. 27. The device of claim 25, wherein the release system comprises parathyroid hormone is in a dried or lyophilized form and a polyethylene glycol. 28. The device of claim 25, wherein the reservoir cap and the input and output leads provide upon the application of electrical current an increase in electrical current density in the reservoir cap relative to the current density in the input and output leads. 29. The device of claim 25, wherein the material forming the reservoir cap has a different electrical resistivity, thermal diffusivity, thermal conductivity, and/or a lower melting temperature than the material forming the input and output leads. 30. The device of claim 25, wherein the reservoir cap and the input and output leads provide upon the application of electrical current an increase in electrical current density in the reservoir cap relative to the current density in the input and output leads, and the material forming the reservoir cap has a different electrical resistivity, thermal diffusivity, thermal conductivity, and/or a lower melting temperature than the material forming the input and output leads.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.